Boston Scientific (BSX) Upgraded to Buy: Here's What You Should Know

Core Viewpoint - Boston Scientific (BSX) has received an upgrade to a Zacks Rank 2 (Buy), indicating a positive outlook based on rising earnings estimates, which significantly influence stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system tracks the Zacks Consensus Estimate, which reflects EPS estimates from sell-side analysts, and is crucial for understanding stock price movements [1][2]. - Changes in earnings estimates are strongly correlated with stock price movements, particularly due to institutional investors who adjust their valuations based on these estimates [4][6]. Business Improvement Indicators - The upgrade in Boston Scientific's rating suggests an improvement in the company's underlying business, which is expected to lead to higher stock prices as investors respond positively [5][10]. - For the fiscal year ending December 2025, Boston Scientific is projected to earn $2.91 per share, reflecting a 15.9% increase from the previous year, with a 5.2% rise in the Zacks Consensus Estimate over the past three months [8]. Zacks Rank System Overview - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have averaged a +25% annual return since 1988 [7][9]. - The upgrade to Zacks Rank 2 places Boston Scientific in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [10].